Cb2 Insights signs a letter of intent with the British company Drug Science for a research program

CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar has joined Steve Darling on Skype from London. The company has been selected as the exclusive research technology platform for the UK's largest medical cannabis project – TWENTY21 Project

Sekar spoke to Proactive about this project and how CB2 will be involved.